dc.contributor.author | Sarsenov, D. | |
dc.contributor.author | Pilanci, K. N. | |
dc.contributor.author | Alco, G. | |
dc.contributor.author | Ordu, C. | |
dc.contributor.author | Celebi, F. | |
dc.contributor.author | Ozmen, V. | |
dc.contributor.author | Ilgun, S. | |
dc.contributor.author | Agacayak, F. | |
dc.contributor.author | Iyigun, Z. Erdogan | |
dc.date.accessioned | 2021-03-03T09:21:03Z | |
dc.date.available | 2021-03-03T09:21:03Z | |
dc.identifier.citation | Pilanci K. N. , Alco G., Ordu C., Celebi F., Sarsenov D., Iyigun Z. E. , Agacayak F., Ilgun S., Ozmen V., "Does trastuzumab increase ONJ development due to zoledronic acid treatment in breast cancer?", BREAST, cilt.24, 2015 | |
dc.identifier.issn | 0960-9776 | |
dc.identifier.other | vv_1032021 | |
dc.identifier.other | av_1c94e01f-0e58-473e-a897-e42499a792c9 | |
dc.identifier.uri | http://hdl.handle.net/20.500.12627/24454 | |
dc.identifier.uri | https://doi.org/10.1016/s0960-9776(15)70157-8 | |
dc.language.iso | eng | |
dc.subject | Klinik Tıp | |
dc.subject | Klinik Tıp (MED) | |
dc.subject | KADIN HASTALIKLARI & DOĞUM | |
dc.subject | Tıp | |
dc.subject | Sağlık Bilimleri | |
dc.subject | Dahili Tıp Bilimleri | |
dc.subject | İç Hastalıkları | |
dc.subject | Onkoloji | |
dc.subject | Cerrahi Tıp Bilimleri | |
dc.subject | Kadın Hastalıkları ve Doğum | |
dc.subject | ONKOLOJİ | |
dc.title | Does trastuzumab increase ONJ development due to zoledronic acid treatment in breast cancer? | |
dc.type | Makale | |
dc.relation.journal | BREAST | |
dc.contributor.department | İstanbul Bilim Üniversitesi , , | |
dc.identifier.volume | 24 | |
dc.contributor.firstauthorID | 221359 | |